A gene-editing therapy may correct a defect in the DYSF gene that drives a form of limb-girdle muscular dystrophy (LGMD), per ...
ECRC researchers developed a CRISPR-based gene therapy targeting dysferlin mutations in muscular dystrophy. By editing and ...
Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting ...
In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a ...
The active genes in the body have to be copied, or transcribed into RNA molecules, which are then processed in a variety of ...
New study reveals crucial protein interactions in Duchenne Muscular Dystrophy, opening doors to more precise and effective ...
Joon Lee, an analyst from Truist Financial, has initiated a new Buy rating on Solid Biosciences (SLDB).Stay Ahead of the Market:Discover ...
A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback